1 | 血液科 | NCCN临床实践指南:急性髓系白血病(2022.V3) | NCCN Clinical Practice Guidelines in Oncology:Acute Myeloid Leukemia( Version 3.2022) | NCCN官网 | 1月份 |
2 | 血液科 | NCCN临床实践指南:儿童霍奇金淋巴瘤(2023.V1) | NCCN Clinical Practice Guidelines in Oncology:Pediatric Hodgkin Lymphoma( Version 1.2023) | NCCN官网 | 1月份 |
3 | 血液科 | 加拿大循证指南:慢性淋巴细胞白血病的一线治疗(更新版) | Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update | Leuk Res.2023 Jan 5;125:107016. | 1月份 |
4 | 血液科 | NCCN临床实践指南:T细胞淋巴瘤(2023.V1) | NCCN Clinical Practice Guidelines in Oncology:T-Cell Lymphomas(Version 1.2023) | NCCN官网 | 1月份 |
5 | 血液科 | 2023 专家共识:高危多发性骨髓瘤的定义和管理 | Experts' consensus on the definition and management of high risk multiple myeloma | Front Oncol.2023 Jan 23;12:1096852. | 1月份 |
6 | 血液科 | NCCN临床实践指南:B细胞淋巴瘤(2023.V1) | NCCN Clinical Practice Guidelines in Oncology:B-Cell Lymphomas( Version 1.2023) | NCCN官网 | 1月份 |
7 | 血液科 | NCCN临床实践指南:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(2023.V2) | NCCN Clinical Practice Guidelines in Oncology:Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma(Version 2.2023) | NCCN官网 | 1月份 |
8 | 血液科 | 2022 RCPCH/RCO指南:早产儿视网膜病的筛查和治疗(更新版) | UK screening and treatment of retinopathy of prematurity Updated 2022 Guidelines | Early Hum Dev.2023 Jan 25;177-178:105715. | 1月份 |
9 | 血液科 | 2023 国际儿童CML专家组建议:儿童和青少年慢性髓性白血病急变期的治疗 | Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations | Leukemia.2023 Jan 27. | 1月份 |
10 | 血液科 | 肿瘤相关抑郁中医诊疗专家共识 |
| 北京中医药大学学报.2023.46(1):12-17. | 1月份 |
11 | 血液科 | 治疗性单采过程管理与质量控制专家共识 |
| 临床输血与检验.2023.25(1):1-9. | 1月份 |
12 | 血液科 | 2023 UKCGG最佳实践共识指南:血液学恶性肿瘤的胚系易患因素 | Germline predisposition to haematological malignancies: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group | Br J Haematol.2023 Feb 6. | 2月份 |
13 | 血液科 | NCCN临床实践指南:B细胞淋巴瘤(2023.V2) | NCCN Clinical Practice Guidelines in Oncology:B-Cell Lymphomas(Version 2.2023) | NCCN官网 | 2月份 |
14 | 血液科 | 2023 UKCGG实践共识指南:具有胚系易患因素的血液恶性肿瘤患者考虑同种异体血液和骨髓移植的管理 | Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Clinical Genetics Group (UKCGG), | Br J Haematol.2023 Feb 14. | 2月份 |
15 | 血液科 | 2023 亚洲专家共识:慢性淋巴细胞白血病的管理 | Expert consensus on the management of chronic lymphocytic leukaemia in Asia | Clin Exp Med.2023 Feb 16. | 2月份 |
16 | 血液科 | 2023 共识声明:代谢性高铁蛋白血症的定义和分类 | Consensus Statement on the definition and classification of metabolic hyperferritinaemia | Nat Rev Endocrinol .2023 Feb 17. | 2月份 |
17 | 血液科 | 淋巴瘤患者生育力保存临床实践中国专家共识 |
| 中华生殖与避孕杂志,2023,43(2):113-122. | 2月份 |
18 | 血液科 | NCCN临床实践指南:急性髓系白血病(2023.V1) | NCCN Clinical Practice Guidelines in Oncology:Acute Myeloid Leukemia(Version 1.2023) | NCCN官网 | 3月份 |
19 | 血液科 | NCCN临床实践指南:造血生长因子(2023.V2) | NCCN Clinical Practice Guidelines in Oncology:Hematopoietic Growth Factors(Version 2.2023) | NCCN官网 | 3月份 |
20 | 血液科 | NCCN临床实践指南:儿童霍奇金淋巴瘤(2023.V2) | NCCN Clinical Practice Guidelines in Oncology:Pediatric Hodgkin Lymphoma (Version 2.2023) | NCCN官网 | 3月份 |
21 | 血液科 | NCCN临床实践指南:儿童急性淋巴细胞白血病(2023.V2) | NCCN Clinical Practice Guidelines in Oncology:Pediatric Acute Lymphoblastic Leukemia(Version 2.2023) | NCCN官网 | 3月份 |
22 | 血液科 | NCCN临床实践指南:急性髓系白血病(2023.V2) | NCCN Clinical Practice Guidelines in Oncology:Acute Myeloid Leukemia( Version 2.2023) | NCCN官网 | 3月份 |
23 | 血液科 | 2023 国际专家声明:成人接受造血细胞移植的体外膜肺氧合 | Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement | NCCN官网 | 3月份 |
24 | 血液科 | 2023 ASFA指南:治疗性单采术的临床应用(第9版) | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis | J Clin Apher.2023 Apr;38(2):77-278. | 4月份 |
25 | 血液科 | 2023 ASTCT指南:造血细胞移植受者侵袭性念珠菌病的管理 | American Society for Transplantation and Cellular Therapy Series, #6: Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients | Transplant Cell Ther.2023 Apr;29(4):222-227. | 4月份 |
26 | 血液科 | NCCN临床实践指南:儿童侵袭性成熟B细胞淋巴瘤(2023.V1) | NCCN Clinical Practice Guidelines in Oncology:Pediatric Aggressive Mature B-Cell Lymphomas( Version 1.202) | NCCN官网 | 4月份 |
27 | 血液科 | NCCN临床实践指南:急性髓系白血病(2023.V3) | NCCN Clinical Practice Guidelines in Oncology:Acute Myeloid Leukemia (Version 3.2023) | NCCN官网 | 4月份 |
28 | 血液科 | NCCN临床实践指南:慢性髓性白血病(2023.V2) | NCCN Clinical Practice Guidelines in Oncology:Chronic Myeloid Leukemia (Version 2.2023) | NCCN官网 | 4月份 |
29 | 血液科 | 2023 DGOU多学科建议:多发性骨髓瘤患者病理性胸腰椎骨折的管理 | Management of Pathological Thoracolumbar Vertebral Fractures in Patients With Multiple Myeloma: Multidisciplinary Recommendations | Global Spine J.2023 Apr;13(1_suppl):85S-93S. | 4月份 |
30 | 血液科 | 2023 法国指南:嗜酸性粒细胞增多症的病因检查和高嗜酸性粒细胞综合征的管理 | French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes | Orphanet J Rare Dis . 2023 Apr 30;18(1):100. | 4月份 |
31 | 血液科 | 2023 EANM共识建议:血液学肿瘤分子影像学和治疗 | European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours | Lancet Haematol.2023 May;10(5):e367-e381. | 5月份 |
32 | 血液科 | 2023 EMN共识:大流行后时代多发性骨髓瘤合并COVID-19患者的管理 | Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN) | Leukemia.2023 May 4. | 5月份 |
33 | 血液科 | 艾沙康唑临床应用专家共识(2023版) |
| 临床血液学杂志.2023.36(5):295-302. | 5月份 |
34 | 血液科 | NCCN临床实践指南:B细胞淋巴瘤(2023.V3) | NCCN Clinical Practice Guidelines in Oncology:B-Cell Lymphomas (Version 3.2023) | NCCN官网 | 5月份 |
35 | 血液科 | 2023 共识意见:泽布替尼治疗恶性淋巴瘤(华氏巨球蛋白血症,边缘区淋巴瘤和套细胞淋巴瘤)未满足的临床需求 | Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus-based position paper from an ad hoc expert panel | Hematol Oncol .2023 May 11. | 5月份 |
36 | 血液科 | NCCN临床实践指南:伴有嗜酸性粒细胞和酪氨酸激酶融合基因的骨髓/淋巴肿瘤(2023.V1) | NCCN Clinical Practice Guidelines in Oncology:Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions (Version 1.2023) | NCCN官网 | 5月份 |
37 | 血液科 | NCCN临床实践指南:系统性肥大细胞增多症(2023.V1) | NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis(Version 1.2023) | NCCN官网 | 5月份 |
38 | 血液科 | 输血相容性检测实验室RhD血型检测策略专家共识 |
| 中国输血杂志.2023.36(5):365-372. | 5月份 |
39 | 血液科 | 2022 BSH指南:重大血红蛋白病的筛查和诊断 | Significant haemoglobinopathies: A guideline for screening and diagnosis: A British Society for Haematology Guideline | Br J Haematol.2023 Jun;201(6):1047-1065. | 6月份 |
40 | 血液科 | 2023 EMN共识报告:双特异性抗体和CAR-T细胞治疗多发性骨髓瘤期间不良事件的预防和管理 | Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network | Lancet Oncol.2023 Jun;24(6):e255-e269. | 5月份 |
41 | 血液科 | NCCN临床实践指南:B细胞淋巴瘤(2023.V4) | NCCN Clinical Practice Guidelines in Oncology:B-Cell Lymphomas (Version 4.2023) | NCCN官网 | 6月份 |
42 | 血液科 | 2023 在嵌合抗原受体T细胞和双特异性抗体治疗多发性骨髓瘤期间感染的预防建议 | Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma | Br J Haematol.2023 Jun 7. | 5月份 |
43 | 血液科 | 2023 国际共识:嗜酸性粒细胞疾病和系统性肥大细胞增多症的分类 | The international consensus classification of eosinophilic disorders and systemic mastocytosis | Am J Hematol.2023 Jun 7. | 6月份 |
44 | 血液科 | NCCN临床实践指南:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(2023.V3) | NCCN Clinical Practice Guidelines in Oncology:Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma(Version 3.2023) | NCCN官网 | 5月份 |
45 | 血液科 | 2022 DGHO建议:恶性血液病患者侵袭性真菌疾病的一级预防 | Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) | J Antimicrob Chemother . 2023 Jun 13;dkad143. | 6月份 |
46 | 血液科 | NCCN临床实践指南:系统性肥大细胞增多症(2023.V3) | NCCN Clinical Practice Guidelines in Oncology:Systemic Mastocytosis(Version 3.2023) | NCCN官网 | 5月份 |